← Back to all trials
Recruiting
NCT07815678
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Conditions: Obesity
Sex: All
Ages: 25 Years – 75 Years
Healthy volunteers: Yes
Phase: PHASE1, PHASE2
Enrollment: 164
Sponsor: Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Location: Research Site Cypress California
Summary
This first-in-human study will evaluate the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of ACCG-2671. It will also evaluate the effect of food on the pharmacokinetics, safety, and tolerability of a single dose. Parts 1 and 2 will enroll healthy participants, and Part 3 will enroll otherwise healthy participants with obesity.
Eligibility Criteria
Inclusion Criteria:
* Signed informed consent
* Men and women with the following at the time of Screening for Part 1 and 2: ≥25 years and ≤65 years of age and BMI ≥18.0 kg/m2 and \
Source: ClinicalTrials.gov (NCT07815678). StuddyBuddy aggregates publicly available trial information.
